Stem cell transplantation for hematological malignancies: Prospects for personalized medicine and co-therapy with mesenchymal stem cells

Current Pharmacogenomics and Personalized Medicine

Volumn 9, Issue 3, 2011, Pages 229-239

  Patel, Shyam A ^a,b   Rameshwar, Pranela ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b The State University of New Jersey   (United States)

Author keywords

Bone marrow; Cxcr4; Graft versus host disease; Hematopoietic niche; Mesenchymal stem cells; Microenvironment; Personalized cell based therapy; Personalized medicine

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; GAMMA INTERFERON; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CELL FUNCTION; CELL HOMING; CELL INTERACTION; CELL TRANSFORMATION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; IMMUNOMODULATION; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; STEM CELL NICHE;

EID: 80052248953     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/187569211796957548     Document Type: Review

References (94)

1. Raanani P, Gafter-Gvili A, Paul M, et al. Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation. Cochrane Database Syst Rev 2008; (4): CD006501.
2. Barton-Burke M, Dwinell DM, Kafkas L, et al. Graft-versus-host disease: a complex long-term side effect of hematopoietic stem cell transplant. Oncology 2008; 22: 31-45.
3. Gomez-Almaguer D, Ruiz-Arguelles GJ, del CT-A, et al. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2008; 14(1):10-15.
4. Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30(1): 42-48.
5. Potian JA, Aviv H, Ponzio NM, et al. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol 2003; 171(7): 3426-3434.
6. Le BK, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 2007; 262(5): 509-525.
7. Weiss L. The hematopoietic microenvironment of the bone marrow: an ultrastructural study of the stroma in rats. Anat Rec 1976; 186(2): 161-184.
8. Gurevitch O, Slavin S, Resnick I, et al. Mesenchymal progenitor cells in red and yellow bone marrow. Folia Biol 2009; 55(1): 27-34.
9. Schick F, Einsele H, Bongers H, et al. Leukemic red bone marrow changes assessed by magnetic resonance imaging and localized 1H spectroscopy. Ann Hematol 1993; 66(1): 3-13.
10. Bainton DF, Maloney MA, Patt HM, et al. Characterization of rabbit stromal fibroblasts derived from red and yellow bone marrow. J Exp Med 1986; 163(2): 400-413.
11. Chitteti BR, Cheng YH, Streicher DA, et al. Osteoblast lineage cells expressing high levels of Runx2 enhance hematopoietic progenitor cell proliferation and function. J Cell Biochem 2010; 111(2): 284-294.
12. Hosokawa K, Arai F, Yoshihara H, et al. Knockdown of Ncadherin suppresses the long-term engraftment of hematopoietic stem cells. Blood 2010; 116(4): 554-563.
13. Patel N, Castillo M, Rameshwar P. An in vitro method to study the effects of hematopoietic regulators during immune and blood cell development. Biol Proced Online 2007; 9: 56-64.
14. Lo CC, Fleming HE, Wu JW, et al. Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche. Nature 2009; 457(7225): 92-96.
15. Butler JM, Nolan DJ, Vertes EL, et al. Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells. Cell Stem Cell 2010; 6(3): 251-264.
16. Dimmeler S. Regulation of bone marrow-derived vascular progenitor cell mobilization and maintenance. Arterioscler Thromb Vasc Biol 2010; 30(6): 1088-1093.
17. de Barros AP, Takiya CM, Garzoni LR, et al. Osteoblasts and bone marrow mesenchymal stromal cells control hematopoietic stem cell migration and proliferation in 3D in vitro model. PLoS One 2010; 5(2): e9093.
18. Mishima S, Nagai A, Abdullah S, et al. Effective ex vivo expansion of hematopoietic stem cells using osteoblastdifferentiated mesenchymal stem cells is CXCL12 dependent. Eur J Haematol 2010; 84(6): 538-546.
19. Iwasaki H, Arai F, Kubota Y, et al. Endothelial protein C receptorexpressing hematopoietic stem cells reside in the perisinusoidal niche in fetal liver. Blood 2010; 116(4): 544-553.
20. Corcoran KE, Patel N, Rameshwar P. Stromal derived growth factor-1alpha: another mediator in neural-emerging immune system through Tac1 expression in bone marrow stromal cells. J Immunol 2007; 178(4): 2075-2082.
21. Carlesso N, Cardoso AA. Stem cell regulatory niches and their role in normal and malignant hematopoiesis. Curr Opin Hematol 2010; 17(4): 281-286.
22. Trumpp A, Essers M, Wilson A. Awakening dormant haematopoietic stem cells. Nat Rev Immunol 2010; 10(3): 201-209.
23. Bhattacharya D, Czechowicz A, Ooi AG, et al. Niche recycling through division-independent egress of hematopoietic stem cells. J Exp Med 2009; 206(12): 2837-2850.
24. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010; 16(11): 2927-2931.
25. Raos M, Nemet D, Bojanic I, et al. Collection and composition of autologous peripheral blood stem cells graft in patients with acute myeloid leukemia: influence on hematopoietic recovery and outcome. Coll Antropol 2010; 34(1): 105-115.
26. Pusic I, DiPersio JF. Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells. Curr Opin Hematol 2010; 17(4): 319-326.
27. Imai H, Sunaga N, Shimizu Y, et al. Clinicopathological and therapeutic significance of CXCL12 expression in lung cancer. Int J Immunopathol Pharmacol 2010; 23(1): 153-164.
28. Gangadhar T, Nandi S, Salgia R. The role of chemokine receptor CXCR4 in lung cancer. Cancer Biol Ther 2010; 9(6): 409-416.
29. Andre F, Xia W, Conforti R, et al. CXCR4 expression in early breast cancer and risk of distant recurrence. Oncologist 2009; 14(12): 1182-1188.
30. Matsusue R, Kubo H, Hisamori S, et al. Hepatic stellate cells promote liver metastasis of colon cancer cells by the action of SDF-1/CXCR4 axis. Ann Surg Oncol 2009; 16(9): 2645-2653.
31. Casper J, Wolff D, Knauf W, et al. Allogeneic hematopoietic stemcell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. J Clin Oncol 2010; 28(20): 3344-3351.
32. Hill BT, Copelan EA. Acute myeloid leukemia: when to transplant in first complete remission. Curr Hematol Malig Rep 2010; 5(2): 101-108.
33. Terwey TH, Kim TD, Arnold R. Allogeneic hematopoietic stem cell transplantation for adult acute lymphocytic leukemia. Curr Hematol Malig Rep 2009; 4(3): 139-147.
34. de WT, Hagemeijer A, Suciu S, et al. Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial. Haematologica 2010; 95(10): 1754-1761.
35. Alchalby H, Kroger N. Reduced-intensity conditioning followed by allogeneic hematopoietic stem cell transplantation in myelofibrosis. Curr Hematol Malig Rep 2010; 5(2): 53-61.
36. Hoff NP, Bruch-Gerharz D. The role of hematopoietic stem-cell transplantation in cutaneous T-cell lymphoma. G Ital Dermatol Venereol 2010; 145(3): 345-359.
37. Meletis J, Terpos E. Transplantation strategies for the management of patients with myelodysplastic syndromes. J BUON 2009; 14(4): 551-564.
38. Oyan B, Koc Y, Ozdemir E, et al. High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and nonmyeloablative allogeneic transplantation in patients with multiple myeloma. Clin Transplant 2009; 23(6): 839-847.
39. Asano-Mori Y. Fungal infections after hematopoietic stem cell transplantation. Int J Hematol 2010; 91(4): 576-587.
40. Choi SW, Levine JE, Ferrara JL. Pathogenesis and management of graft-versus-host disease. Immunol Allergy Clin North Am 2010; 30(1): 75-101.
41. Li M, Gao C, Li H, et al. Allogeneic haematopoietic stem cell transplantation as a salvage strategy for relapsed or refractory nasal NK/T-cell lymphoma. Med Oncol 2010.
42. Tolar J, Hippen KL, Blazar BR. Immune regulatory cells in umbilical cord blood: T regulatory cells and mesenchymal stromal cells. Br J Haematol 2009; 147(2): 200-206.
43. Shapira MY, Resnick IB, Dray L, et al. A new induction protocol for the control of steroid refractory/dependent acute graft versus host disease with alefacept and tacrolimus. Cytotherapy 2009; 11(1): 61-67.
44. Mutis T, Brand R, Gallardo D, et al. Graft-versus-host driven graftversus- leukemia effect of minor histocompatibility antigen HA-1 in chronic myeloid leukemia patients. Leukemia 2010; 24(7): 1388-1392.
45. Gutierrez-Aguirre CH, Ruiz-Arguelles G, Cantu-Rodriguez OG, et al. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method. Ann Hematol 2010; 89(10): 1045-1052.
46. Boatsman EE, Fu CH, Song SX, et al. Graft-versus-leukemia effect on infant lymphoblastic leukemia relapsed after sibling hematopoietic stem cell transplantation. J Pediatr Hematol Oncol 2010; 32(2): e57-e60.
47. Biernacki MA, Marina O, Zhang W, et al. Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. Cancer Res 2010; 70(3): 906-915.
48. Shustov AR, Gooley TA, Sandmaier BM, et al. Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas. Br J Haematol 2010; 150(2): 170-178.
49. Kohrt HE, Pillai AB, Lowsky R, et al. NKT cells, Treg, and their interactions in bone marrow transplantation. Eur J Immunol 2010; 40(7): 1862-1869.
50. Baron F, Lechanteur C, Willems E, et al. Cotransplantation of mesenchymal stem cells might prevent death from graft-versushost disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant 2010; 16(6): 838-847.
51. Casiraghi F, Azzollini N, Cassis P, et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol 2008; 181(6): 3933-3946.
52. Patel SA, Meyer JR, Greco SJ, et al. Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. J Immunol 2010; 184(10): 5885-5894.
53. Momin EN, Vela G, Zaidi HA, et al. The Oncogenic Potential of Mesenchymal Stem Cells in the Treatment of Cancer: Directions for Future Research. Curr Immunol Rev 2010; 6(2): 137-148.
54. Chen CH, Shu KH, Su YH, et al. Cotransplantation of hepatic stellate cells attenuates the severity of graft-versus-host disease. Transplant Proc 2010; 42(3): 971-975.
55. Meuleman N, Tondreau T, Ahmad I, et al. Infusion of mesenchymal stromal cells can aid hematopoietic recovery following allogeneic hematopoietic stem cell myeloablative transplant: a pilot study. Stem Cells Dev 2009; 18(9): 1247-1252.
56. Ringden O. Mesenchymal stromal cells as first-line treatment of graft failure after hematopoietic stem cell transplantation. Stem Cells Dev 2009; 18(9): 1243-1246.
57. Lim JH, Lee MH, Yi HG, et al. Mesenchymal stromal cells for steroid-refractory acute graft-versus-host disease: a report of two cases. Int J Hematol 2010; 92(1): 204-207.
58. Rameshwar P. Casting doubt on the safety of off-the-shelf mesenchymal stem cells for cell therapy. Mol Ther 2009; 17(2): 216-218.
59. Lian Q, Zhang Y, Zhang J, et al. Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. Circulation 2010; 121(9): 1113-1123.
60. Guo M, Sun Z, Sun QY, et al. A modified haploidentical nonmyeloablative transplantation without T cell depletion for highrisk acute leukemia: successful engraftment and mild GVHD. Biol Blood Marrow Transplant 2009; 15(8): 930-937.
61. Masuda S, Ageyama N, Shibata H, et al. Cotransplantation with MSCs improves engraftment of HSCs after autologous intra-bone marrow transplantation in nonhuman primates. Exp Hematol 2009; 37(10):1250-1257.
62. Longoni B, Szilagyi E, Quaranta P, et al. Mesenchymal stem cells prevent acute rejection and prolong graft function in pancreatic islet transplantation. Diabetes Technol Ther 2010; 12(6): 435-446.
63. Augello A, Tasso R, Negrini SM, et al. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum 2007; 56(4): 1175-1186.
64. Mousavi NN, Jaberipour M, Razmkhah M, et al. Mesenchymal stem cells do not suppress lymphoblastic leukemic cell line proliferation. Iran J Immunol 2009; 6(4): 186-194.
65. Ye Z, Wang Y, Xie HY, et al. Immunosuppressive effects of rat mesenchymal stem cells: involvement of CD4+CD25+ regulatory T cells. Hepatobiliary Pancreat Dis Int 2008; 7(6): 608-614.
66. Zhang Q, Shi S, Liu Y, et al. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J Immunol 2009; 183(12): 7787-7798.
67. Constantin G, Marconi S, Rossi B, et al. Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells 2009; 27(10): 2624-2635.
68. Gonzalez MA, Gonzalez-Rey E, Rico L, et al. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology 2009; 136(3): 978-989.
69. Le BK, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371(9624): 1579-1586.
70. Tang KC, Trzaska KA, Smirnov SV, et al. Down-regulation of MHC II in mesenchymal stem cells at high IFN-gamma can be partly explained by cytoplasmic retention of CIITA. J Immunol 2008; 180(3): 1826-1833.
71. Ren G, Zhang L, Zhao X, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2(2): 141-150.
72. Renner P, Eggenhofer E, Rosenauer A, et al. Mesenchymal stem cells require a sufficient, ongoing immune response to exert their immunosuppressive function. Transplant Proc 2009; 41(6): 2607-2611.
73. Najar M, Rouas R, Raicevic G, et al. Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy 2009; 11(5): 570-583.
74. Le BK, Samuelsson H, Gustafsson B, et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 2007; 21(8): 1733-1738.
75. Ringden O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81(10): 1390-1397.
76. Perez Simon JA, Lopez-Villar O, Andreu EJ, et al. Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial. Haematologica 2011.[epub ahead of print]
77. Wu KH, Chan CK, Tsai C, et al. Effective Treatment of Severe Steroid-Resistant Acute Graft-Versus-Host Disease With Umbilical Cord-Derived Mesenchymal Stem Cells. Transplantation 2011. [epub ahead of print]
78. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449(7162): 557-563.
79. Shinagawa K, Kitadai Y, Tanaka M, et al. Mesenchymal stem cells enhance growth and metastasis of colon cancer. Int J Cancer 2010; 127(10): 2323-2333.
80. Roorda BD, Elst A, Boer TG, et al. Mesenchymal stem cells contribute to tumor cell proliferation by direct cell-cell contact interactions. Cancer Invest 2010; 28(5): 526-534.
81. Mishra PJ, Mishra PJ, Humeniuk R, et al. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res 2008; 68(11): 4331-4339.
82. Gazziola C, Cordani N, Wasserman B, et al. Malignant fibrous histiocytoma: a proposed cellular origin and identification of its characterizing gene transcripts. Int J Oncol 2003; 23(2): 343-351.
83. Avellini C, Alampi G, Cocchi V, et al. Malignant sarcomatoid mesothelioma of the pleura: a histological and immunohistological study of a case. Pathologica 1991; 83(1085): 335-340.
84. Yamamoto M, Kamigaki T, Yamashita K, et al. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer. Oncol Rep 2009; 22(2): 337-343.
85. Flavell RA, Sanjabi S, Wrzesinski SH, et al. The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 2010; 10(8): 554-567.
86. Bauer M, Su G, Casper C, et al. Heterogeneity of gene expression in stromal fibroblasts of human breast carcinomas and normal breast. Oncogene 2010; 29(12): 1732-1740.
87. Haviv I, Polyak K, Qiu W, et al. Origin of carcinoma associated fibroblasts. Cell Cycle 2009; 8(4): 589-595.
88. Littlepage LE, Egeblad M, Werb Z. Coevolution of cancer and stromal cellular responses. Cancer Cell 2005; 7(6): 499-500.
89. Huang M, Li Y, Zhang H, et al. Breast cancer stromal fibroblasts promote the generation of CD44+. J Exp Clin Cancer Res 2010; 29: 80.
90. Liu T, Lin B, Qin J. Carcinoma-associated fibroblasts promoted tumor spheroid invasion on a microfluidic 3D co-culture device. Lab Chip 2010; 10(13): 1671-1677.
91. Ianosi G, Neagoe D, Buteica E, et al. Giant retroperitoneal sarcomas. Rom J Morphol Embryol 2007; 48(3): 303-308.
92. Cappelli B, Aiuti A. Gene therapy for adenosine deaminase deficiency. Immunol Allergy Clin North Am 2010; 30(2): 249-260.
93. Gaspar HB. Bone marrow transplantation and alternatives for adenosine deaminase deficiency. Immunol Allergy Clin North Am 2010; 30(2): 221-236.
94. Croitoru-Lamoury J, Lamoury FM, Zaunders JJ, et al. Human mesenchymal stem cells constitutively express chemokines and chemokine receptors that can be upregulated by cytokines, IFNbeta, and Copaxone. J Interferon Cytokine Res 2007; 27(1): 53-64.